<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00498069</url>
  </required_header>
  <id_info>
    <org_study_id>2007-1</org_study_id>
    <nct_id>NCT00498069</nct_id>
  </id_info>
  <brief_title>Study of Autologous Bone Marrow Concentrate for the Treatment of Critical Limb Ischemia (CLI)</brief_title>
  <official_title>Feasibility Study of the Safety and Activity of Autologous Bone Marrow Aspirate Concentrate (BMAC) for the Treatment of Critical Limb Ischemia Due to Peripheral Arterial Occlusive Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harvest Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Harvest Technologies</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Injections of concentrated bone marrow mononuclear cells into ischemic tissues will result in&#xD;
      vasculogenesis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bone marrow aspirate is collected and processed by centrifugation to remove red blood cells.&#xD;
      The buffy coat is concentrated by removing plasma. The resultant concentrate of cells is&#xD;
      injected into ischemic tissues of the lower limb.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To be determined by data from this feasibility study</measure>
    <time_frame>3 mos &amp; 5 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Ischemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injection of autologous bone marrow concentrate into ischemic tissues of the lower extremity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Injection of placebo into ischemic tissues of the lower extremity</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Harvest Smartprep2 BMAC System</intervention_name>
    <description>injection of 40cc bmac</description>
    <arm_group_label>1</arm_group_label>
    <other_name>SmartPReP2 BMAC System</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SmartPReP2 BMAC System</intervention_name>
    <description>Injection of autologous bone marrow concentrate prepared with the SmartPReP2 BMAC System</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>injection of placebo into ischemic tissue of the lower extremity</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Critical Limb Ischemia per protocol (see diagnostic criteria #2) with&#xD;
             regard to the study limb.&#xD;
&#xD;
        Existence of a PAOD with clinical presentation corresponding to Rutherford Category 4 or&#xD;
        Category 5 as defined in the reporting standards adopted by the Society of Vascular&#xD;
        Surgeons (table 1)&#xD;
&#xD;
          -  Patient meets at least one of the following diagnostic criteria in the study limb:&#xD;
&#xD;
               -  Ankle artery occlusion pressure absolute &lt;50 mmHg or ABI &lt;0.4&#xD;
&#xD;
               -  Toe artery occlusive pressure &lt; 40mm Hg or TBI (&lt;0.4)&#xD;
&#xD;
               -  TcPO2 &lt;20 mmHg lying down breathing room air.&#xD;
&#xD;
          -  There is no reasonable open surgical or endovascular revascularization option as&#xD;
             determined by the treating vascular specialist. Factors that may contribute to the&#xD;
             determination of inoperability may include:&#xD;
&#xD;
               -  Anatomical considerations&#xD;
&#xD;
                    -  No outflow targets&#xD;
&#xD;
                    -  No appropriate conduit (i.e. vein for bypass)&#xD;
&#xD;
                    -  Long segment occlusions or calcified lesions that predict poor outcome with&#xD;
                       endovascular approaches.&#xD;
&#xD;
               -  High risk medical conditions&#xD;
&#xD;
                    -  Unstable cardiac disease.&#xD;
&#xD;
                    -  Renal insufficiency&#xD;
&#xD;
               -  History of prior failed revascularization attempts&#xD;
&#xD;
               -  The patient's unsuitability must be confirmed by 2 qualified physicians.&#xD;
&#xD;
                    -  The attending vascular surgeon will provide the primary assessment.&#xD;
&#xD;
                    -  The confirmatory opinion must come from a fully licensed physician. (not a&#xD;
                       resident)&#xD;
&#xD;
                    -  If anatomical considerations are invoked, the second physician may be a&#xD;
                       vascular surgeon, interventional radiologist, cardiologist, or vascular&#xD;
                       medicine specialist.&#xD;
&#xD;
                    -  If medical co-morbidity is deemed the high risk aspect, then the&#xD;
                       confirmatory opinion may be obtained from an internist, family physician,&#xD;
                       cardiologist, vascular medicine, nephrologists, or vascular surgeon.&#xD;
&#xD;
          -  Age &gt;18 years and ability to understand the planned treatment&#xD;
&#xD;
          -  Subject has read and signed the IRB approved Informed Consent form&#xD;
&#xD;
          -  Patients for whom the following medication(s) is prescribed must have a one month&#xD;
             stable baseline of appropriate/maximally tolerated therapy prior to enrollment:&#xD;
             Plavix/asprin therapy, anticoagulation therapy, cholesterol lowering agent, and or&#xD;
             blood pressure medication&#xD;
&#xD;
          -  Hematocrit ≥ 28.0%, White Blood Cell count ≤ 14,000, Platelet count ≥ 50,000,&#xD;
             Creatinine ≤ 2.0 mg / dL, INR ≤ 1.6 unless on Coumadin, or PTT &lt;1.5 x control (to&#xD;
             avoid bleeding complications) Patients on Coumadin will be corrected prior to the&#xD;
             procedure and must have an INR&lt;1.6 at the time of randomization/surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Life expectancy &lt;6 months due to concomitant illnesses&#xD;
&#xD;
          -  History of bone marrow diseases (especially NHL, MDS) that prohibit transplantation&#xD;
&#xD;
          -  Terminal renal failure with existing dependence on dialysis&#xD;
&#xD;
          -  Known active malignancy or results outside of normal limits from the following tests:&#xD;
             PAP, Chest X-ray, PSA, Mammogram, Hemoccult unless follow-up studies reveal patient to&#xD;
             be cancer free..&#xD;
&#xD;
          -  Poorly controlled diabetes mellitus (HgbA1C&gt;10%)&#xD;
&#xD;
          -  Medical risk that precludes anesthesia (conscious sedation), or ASA Class 5&#xD;
&#xD;
          -  Life-threatening complications of the ischemia necessitating immediate amputation&#xD;
&#xD;
          -  Uncorrected iliac artery occlusion on index side&#xD;
&#xD;
          -  No Doppler signal in the foot (ABI =0)&#xD;
&#xD;
          -  Extensive necrosis of the index limb or other conditions that make amputation&#xD;
             inevitable (Rutherford Category 6)&#xD;
&#xD;
          -  Active clinical infection being treated by antibiotics within one week of enrollment&#xD;
&#xD;
          -  Treatment with immunosuppressant drugs (including Prednisone &gt; 5 mg per day).&#xD;
&#xD;
          -  Female who is pregnant or nursing, or of child bearing potential and is not using a&#xD;
             reliable birth control method.&#xD;
&#xD;
          -  Underwent a major open cardiovascular surgical procedure (carotid endarterectomy,&#xD;
             arterial aneurysm or bypass surgery, or coronary artery bypass surgery) or a&#xD;
             myocardial infarction within the 3 months prior to randomization&#xD;
&#xD;
          -  Cerebrovascular accident within 6 months prior to randomization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of South Florida Department of Vascular Surgery at Tampa General</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Vascular Group at Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roper St. Francis Hospital</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>July 5, 2007</study_first_submitted>
  <study_first_submitted_qc>July 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2007</study_first_posted>
  <last_update_submitted>March 17, 2015</last_update_submitted>
  <last_update_submitted_qc>March 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Critical limb ischemia due to peripheral arterial occlusive disease</keyword>
  <keyword>Autologous bone marrow concentrate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

